Significance of Decreasing Rate of HIV and HBV Co-infection in a Nationwide Korean HIV/AIDS Cohort.

From December 2006 to December 2016, 1093 human immunodeficiency virus (HIV) individuals < 70 years enrolled in Korea human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS) cohort were analyzed to investigate the prevalence of HIV/HBV co-infection rate and hepatitis B virus surface antibody (HBsAb) positive rate based on birth year. The HBV co-infection prevalence rate was the highest (8.8%) in patients born between 1960 and 1964 and the lowest (0%) among those born between 1995 and 1999. A decreasing linear trend of HBV co-infection rate was observed according to the 5-year interval changes. HBsAb-positive rate was only 58.1% in our study. The national HBV vaccination programs have effectively lowered the HBV co-infection rate in HIV population. However, it is identified that the HIV population has low HBsAb positive rate. Further evidences supporting efficacy of booster immunization for HBsAb negative HIV patients are required and efforts should be made to increase HBsAb positive rates among HIV patients to prevent horizontal transmission.

Approximately 10% of the population infected with human immunodeficiency virus (HIV) has concurrent chronic hepatitis B, with co-infection rates more common in areas of high prevalence for both viruses.12 Korea was classified as a high hepatitis B virus (HBV) endemic area before implementing universal vaccination; in the 1980s, around 11% of neonates in Korea were infected with HBV through vertical transmission.3 Efforts to maintain the HBV vaccination rate above 95% has resulted in the average prevalence rate of hepatitis B decreasing to 3% since 2010. The hepatitis B virus surface antigen (HBsAg) positive rates of younger age groups markedly declined to 0.3% in 2016.4 However, there has been no further decline ever since and hepatitis B continues to remain a high prevalence disease in Korea. The fact that hepatitis B is still identified with low probability does not preclude the possibility of a horizontal transmission. While the prevalence rate of hepatitis B is an estimated 5%, as per the Korea HIV/AIDS (acquired immune deficiency syndrome) cohort in 2017,5 seroprevalence of HBV among HIV patients has been rarely reported in Korea after introduction of HBV vaccination as supplementary immunization activity in 1985 and the national vaccination program (NIP) for newborns in 1995.6 Therefore, we aimed to evaluate the HBsAg, HBsAb status and the effect of HBV vaccination programs in HIV patients.

The Korea HIV/AIDS cohort is a multicenter, prospective study consisting of 15 university hospitals nationwide and funded by the Korean Centers for Disease Control and Prevention (KCDC). This cohort has an ongoing enrollment of HIV-infected adult patients older than 18 years. We analyzed HIV individuals enrolled between December 2006 and December 2016. To evaluate the prevalence of HBV co-infection rate and HBsAb status among HIV-infected persons, we investigated the presence of HBsAg and HBsAb based on the year of birth.

According to the HIV/AIDS management guidelines of KCDC, HIV infection was screened for using enzyme immunoassays (EIA) and confirmed with western blotting. HBV infection was defined based on HBsAg positivity with or without protective antibodies. HBsAb positivity was confirmed by a positive enzyme linked immunosorbent assay test. The seropositivity of HBsAg was determined by cut-off index of HBsAg > 1.0 and HBsAb > 10 mIU/mL.

The statistical analyses are performed with descriptive statistics and linear regression. The statistical analyses were performed using R statistics ver. 3.1 (R Foundation for Statistical Computing, Vienna, Austria).

A total of 1,093 individuals (mean age, 47 years; interquartile range [IQR], 39–56) were included for analysis (Fig. 1). Most participating patients were men (1,028/1,093; 94.15%) and Korean ethnicity (1,079/1,093; 98.7%). The main route of transmission was sexual contact accounting for 1058 (96.8%) patients. Further, 127 (11.6%) patients experienced disease transmission from foreign countries (Table 1).

Fig. 1

Profile of enrolled patients.

HIV = human immunodeficiency virus, HBV = hepatitis B virus, HBsAb = hepatitis B virus surface antibody.

Table 1

Patients' baseline characteristics according to birth year

Variables		Birth year			Total (n = 1,093)	P value
		Before 1985 (n = 935)	1985–1995 (n = 151)	After 1995 (n = 7)
Gender						0.140
	Women	61 (6.5)	4 (2.6)	0 (0.0)	65 (5.9)
	Men	874 (93.5)	147 (97.4)	7 (100.0)	1,028 (94.1)
Age, yr		50.0 (43.0–57.0)	30.0 (29.0–32.0)	24.0 (23.0–24.0)	47.0 (39.0–56.0)	< 0.001
Ethnicity						0.009
	Korean	924 (98.8)	149 (98.7)	6 (85.7)	1,079 (98.7)
	Othersa	11 (1.2)	2 (1.3)	1 (14.3)	14 (1.3)
Transmission route of HIV						0.723
	Sexual contact	905 (96.8)	146 (96.7)	7 (100.0)	1,058 (96.8)
	Others	3b (0.3)	2c (1.3)	0 (0.0)	5 (0.5)
	Reception of blood/product	2 (0.2)	0 (0.0)	0 (0.0)	2 (0.2)
	Unknown	25 (2.7)	3 (2.0)	0 (0.0)	28 (2.6)
Transmitted area						0.107
	In Korea	605 (64.7)	95 (62.9)	6 (85.7)	706 (64.6)
	Foreign country	115 (12.3)	11 (7.3)	1 (14.3)	127 (11.6)
	Unknown	215 (23.0)	45 (29.8)	0 (0.0)	260 (23.8)
Fatty liver						0.528
	Yes	18 (1.9)	1 (0.7)	0 (0.0)	19 (1.7)
	No	872 (93.3)	146 (96.7)	7 (100.0)	1,025 (93.8)
	Unknown	45 (4.8)	4 (2.6)	0 (0.0)	49 (4.5)
Liver cirrhosis						0.539
	Yes	7 (0.7)	0 (0.0)	0 (0.0)	7 (0.6)
	No	882 (94.3)	147 (97.4)	7 (100.0)	1,036 (94.8)
	Unknown	46 (4.9)	4 (2.6)	0 (0.0)	50 (4.6)
Hepatocellular carcinoma						0.416
	No	890 (95.2)	147 (97.4)	7 (100.0)	1,044 (95.5)
	Unknown	45 (4.8)	4 (2.60)	0 (0.0)	49 (4.5)
Hepatitis B vaccination history						0.033
	Yes	283 (30.3)	63 (41.7)	3 (42.9)	349 (31.9)
	No	389 (41.6)	53 (35.1)	4 (57.1)	446 (40.8)
	Unknown	263 (28.1)	35 (23.2)	0 (0.0)	298 (27.3)
HBsAg						0.125
	Positive	54 (5.8)	3 (2.0)	0 (0.0)	57 (5.2)
	Negative	881 (94.2)	148 (98.0)	7 (100.0)	1,036 (94.8)
HBsAb						0.161
	Positive	539 (57.6)	94 (62.3)	2 (28.6)	635 (58.1)
	Negative	396 (42.4)	57 (37.7)	5 (71.4)	458 (41.9)
HCV						0.905
	Positive	21 (2.2)	3 (2.0)	0 (0.0)	24 (2.2)
	Negative	914 (97.8)	148 (98.0)	7 (100.0)	1,069 (97.8)

Values are presented as medians (interquartile range) or number (%).

HIV = human immunodeficiency virus, HBsAg = hepatitis B virus surface antibody, HCV = hepatitis C virus.

aOthers denote non-Korean Asian patients; b1 acupuncture, 1 needle stick injury, 1 intravenous drug injection; c1 tattoo, 1 intravenous drug injection.

The HIV/HBV co-infection rate was identified in 5.2% (57/1,093) and HBV/HCV/HIV co-infection was only found in one patient born between 1960 and 1964. The HIV/HBV co-infection incidence was highest (8.8%; 12/174) among patients in the birth years between 1960 and 1964 and lowest (0%; 0/7) among those born between 1995 and 1999. A decreasing linear trend was observed with 5-year intervals (Fig. 2). Before year 1985, the proportion of HBsAg positivity was 54 (5.8%), but after 1985, between 1985 and 1995, the HBsAg positivity reduced to 3 (2.0%), and no hepatitis B co-infection was identified since 1995.

Fig. 2

Decreasing human immunodeficiency virus/hepatitis B virus co-infection incidence rate according to the birth year in 5-year intervals.

HBsAg = hepatitis B virus surface antigen, HBsAb = hepatitis B virus surface antibody.

The HBsAb positive rate was 58.1% (635/1,093) in the total HIV population (Table 1). The HBsAb positive rate was highest 64.8% (59/91) among patients born between 1985 and 1989. However, HBsAb positive rate was the lowest 28.6% (2/7) among patients born between 1995 and 1999 despite the rate of hepatitis B vaccination history being 42.9% (3/7) (Fig. 2).

The HBsAb positive rate was found in 198 (56.7%) out of a total of 349 patients with HBV vaccination history. Furthermore, the HBsAb positive rate ranged from 33.3% to 66.7% in patients born between 1950 and 1999. HBsAg was found to be positive in four patients born before 1985 (1.1%) out of 349 who said they had a history of vaccination.

Next, HBsAb positivity confirmed in 635 patients were analyzed, and 198 (31.2%) of these patients had an HBV vaccination history. Of the remaining patients, 185 (29.1%) could not remember their HBV vaccination history and 252 (39.7%) stated that they had never been vaccinated. The result did not differ from the results of the whole cohort, regardless of the patients' memory and status of HBsAb.

After introduction of hepatitis B vaccination, a significant decline in the prevalence of HBsAg positivity among HIV-positive patients was observed in our study. This result was similar to Taiwan HIV study which showed declined prevalence of HBsAg positivity from 16% to 4% after introduction of universal HBV vaccination in 1986.7 However, Korea still has a higher HBV prevalence rate than some other countries. Until now, the estimated prevalence was approximately 3% in 2016.4 The prevalence of HIV-HBV co-infection was 5.2% in our study, which showed a higher prevalence of HBV infection in HIV patients than in the general population. This is consistent with other previous studies.589 This may be caused by similarities in routes of transmission and risk factors between HBV and HIV,101112 or lower incidences of spontaneous loss of HBsAg because of HIV-induced impairment of host innate and adaptive immunity.13 Given that most HIV infections in Korea are caused by sexual contact (96.8%) and that the vaccination rate for hepatitis B in Korean children is high, it is estimated that the chance of infection through sexual contact has increased, while the chance of infection by vertical infection has decreased.14 Currently, more than 1,000 new HIV infected patients are identified in Korea every year. HBV transmission may still occur in unvaccinated or uninfected adults and can lead to chronicity. A retrospective study conducted in a west China hospital showed that the prevalence of HIV/HBV co-infection was 14.4% among 894 HIV-infected patients. A high prevalence of HIV/HBV co-infection was observed and the rate for HIV-infected patients who were effectively vaccinated against HBV was fewer than 10%.15 Hepatitis B vaccination is consider with priority for people living with HIV.

However, despite the NIPs, adult HBsAb positive rate was reported to be 70.2% in Korean general population.16 Our study identified that the HIV population has lower HBsAb positive rates compared with general population. The HBsAb positive rate was only 56.7% among those known to have been vaccinated against HBV. It is assumed that there are more possibilities for transmission and infection by hepatitis B in the HIV population.

In our study, HBsAb positive rate of young HIV patients under 30 years old was identified 55.2% (37/67). A previous study conducted in Korea showed that HBsAb did not persist as protective titer despite complete HBV vaccination.6 The efficacy of vaccines may have a waning effect in Korea not only in general population but also in HIV patients. This would be a serious cause for concern among young HIV patients. A study conducted in Hong Kong indicated that decreased HBsAg carriage could be associated simultaneously with decreased seroprotection; thus, the former neonatal vaccination should not be considered as evidence of adequate seroprotection.17 Several studies showed that the HBsAb titer below the protective level after HBV vaccination could have protective effect against HBV infection because of anamnestic effect of HBsAb. However, it was not verified in HIV patients so called hyporesponders, eliciting the necessity of booster vaccination after adulthood.1819 Vaccine-induced immunity should not be taken for granted from the period of adolescence onwards especially in HIV patients. Appropriate immunization of hepatitis B may be needed to prevent new HBV infections.20

For HIV patients, the effect of vaccination may differ according to immunity. Factors associated with impaired HBV vaccine response include older age, uncontrolled HIV replication, and low nadir CD4+ cell counts.21 We believe that appropriate vaccination policies are needed especially in HIV patients with these characteristics. National health plans should provide specific planning for HIV patients.

Our study has some limitations. First, because of the unfilled and missing data, we could not identify patients who have recovered from past HBV infections. Second, we could not distinguish between patients being infected with HBV prior to HIV infection, and whether they were infected by horizontal transmission sharing a same path with HIV. Third, since 1995, only seven patients were identified with HIV/HBV co-infection. This very small number of patients could have introduced a bias in our results.

In conclusion, our findings showed that the national HBV vaccination programs were effective in decreasing the HBV co-infection rate in HIV population. However, the HIV-HBV co-infection rate is still high and the HBsAb positive rate is low in Korea. Further evidences supporting efficacy of booster immunization for HBsAb negative HIV patients are required and as hepatitis B vaccine does not always provide life-long protection, efforts should be made to increase HBsAb positive rates among HIV patients to prevent horizontal transmission.

Ethics statement

This study was approved by the Institutional Review Board (IRB) of Kyungpook National University College of Medicine (approval No. 2011-01-048). All participants provided written informed consent, and ethics approval was obtained from the IRB of each participating institute.